-
A large health-record analysis found that glucosamine use was associated with a 25% higher likelihood of mild cognitive impairment progressing to dementia. Lab experiments suggest the popular joint supplement may intensify an abnormal sugar-tagging process in the Alzheimer’s brain, although researchers say clinical trials are needed to determine whether it actually causes harm.
-
Tirzepatide, sold as Mounjaro and Zepbound, activated calorie-burning brown fat in obese mice, revealing a potential metabolic effect beyond appetite suppression. If confirmed in humans, the finding could help explain the drug’s powerful benefits and inspire more comprehensive treatments for obesity and diabetes.
-
Pain and fatigue in rheumatoid arthritis can persist even after inflammation improves, with depression, poor sleep, obesity, smoking, and chronic pain potentially helping sustain symptoms. Researchers say identifying these hidden drivers could prevent unnecessary medication changes and lead to more personalized treatment.
-
Scientists discovered a surprising energy paradox in the brain during REM sleep, the stage most closely associated with dreaming. Blood supply to the brain begins increasing even before REM starts, but neurons’ immediately available energy, measured as ATP, then drops. The finding suggests that dreaming may require such intense internal processing that neurons consume energy faster than it can be replenished.
-
Scientists have found that a famous 2-billion-year-old chemical signature, once thought to record a massive global change in Earth’s carbon cycle, may instead have been produced by local magma, hydrocarbons, and methane-eating microbes. The discovery raises new questions about what was really happening as oxygen transformed the young planet.
